KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Receivables (2016 - 2025)

Historic Receivables for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q1 2025 value amounting to $8.6 million.

  • Xenon Pharmaceuticals' Receivables rose 93829.53% to $8.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $8.6 million, marking a year-over-year increase of 93829.53%. This contributed to the annual value of $2.9 million for FY2024, which is 23615.56% up from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Receivables stood at $8.6 million for Q1 2025, which was up 93829.53% from $2.9 million recorded in Q4 2024.
  • Xenon Pharmaceuticals' 5-year Receivables high stood at $8.6 million for Q1 2025, and its period low was $805000.0 during Q3 2023.
  • Its 5-year average for Receivables is $2.5 million, with a median of $2.5 million in 2022.
  • Its Receivables has fluctuated over the past 5 years, first tumbled by 6756.65% in 2023, then skyrocketed by 93829.53% in 2025.
  • Xenon Pharmaceuticals' Receivables (Quarter) stood at $2.8 million in 2021, then crashed by 64.34% to $986000.0 in 2022, then decreased by 11.36% to $874000.0 in 2023, then surged by 236.16% to $2.9 million in 2024, then soared by 194.38% to $8.6 million in 2025.
  • Its last three reported values are $8.6 million in Q1 2025, $2.9 million for Q4 2024, and $938000.0 during Q3 2024.